View Older Stories View More Recent Stories
-
Winona Capital Invests in Diono® to Fuel Growth and Innovation
-
Roth Capital Downgrades NVIDIA (NVDA) to Neutral
-
Roth Capital Partners Lowers PT on Planar Systems (PLNR) Anticipating 'Lull in Digital Signage'
-
Concerns Over Canadian Solar's (CSIQ) Q2 Outlook Likely 'Misplaced' - Roth Capital
-
Regeneron Pharma (REGN) PT Lifted to $490 at Roth Capital
-
ROTH Capital Partners Expands Technology with Addition of Brian Alger, CFA as a Senior Research Analyst In Technology
-
Roth Capital Upgrades SodaStream International (SODA) to Buy
-
Notable Analyst Rating Changes 5/6: (SRPT) (AXP) (YNDX) Upgraded; (NSM) (DEI) (FNFG) Downgraded
-
Pre-Open Stock Movers 05/06: (GEVA) (BRDR) (FATE) (MGI) Higher; (WLT) (ZU) (NDLS) Lower (more...)
-
Roth Capital Starts Digital Turbine (APPS) at Buy, PT $12
-
Roth Capital Upgrades GP Strategies (GPX) to Buy
-
Roth Capital Downgrades CorMedix (CRMD) to Neutral
-
Applied Genetic Tech (AGTC) Fundamentals Unchanged Amid NIH Publication on LCA w/ RPE65 Mutation
-
Roth Capital Upgrades Web.com Group (WWWW) to Buy
-
Cytori Therapeutics (CYTX) Prices Direct Offering at 77c/Unit
-
Cytori Prices Registered Direct Offering Providing for up to $25 million in Equity Financing
-
Roth Capital Downgrades PTC Therapeutics (PTCT) to Neutral
-
Roth Capital Starts Gaiam Inc. (GAIA) at Buy
-
Hannon Armstrong Sustainable Infrastructure Capital, Inc. Announces the Closing of its Public Offering of Common Stock
-
Roth Capital Starts Halcon Resources (HK) at Buy
-
Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following BL-8040 Update
-
Challenged Athletes Foundation to Celebrate Unbreakable Athletic Spirit at Ninth Annual Gala in New York City
-
Roth Capital Starts Marathon Patent Group (MARA) at Buy
-
Roth Nudges PT on Ballard Power (BLDP) up to $2.55; Recent Business Wins Set Topline Growth Trajectory
-
RedHill Biopharma Reports Results for the First Quarter of 2015
-
Lipocine Announces Closing of $34.8 Million Common Stock Offering
-
Lipocine Prices $30.2 Million Public Offering of Common Stock
-
Lipocine Prices $30.2 Million Public Offering of Common Stock
-
Hannon Armstrong Sustainable Infrastructure Capital, Inc. Announces the Pricing of its Public Offering of Common Stock
-
Roth Capital Starts Enerpulse Technologies (ENPT) at Buy
-
ROTH Capital Partners Expands Healthcare Practice with Addition of Michael Higgins as a Senior Research Analyst – Specialty Pharmaceuticals/Biotechnology
-
Roth Capital Downgrades Celladon Corp (CLDN) to Neutral
-
Cellceutix Selects Independent Directors and Committee Members
-
Roth Capital Starts RAVE Restaurant (RAVE) at Buy
-
Roth Capital Boosts PT on Green Plains (GPRE) to $40; Notes Improving Market Conditions, MLP Outlook
-
Lipocine (LPCN) Prices 4.65M Common at $6.50/Sahre
-
Lipocine Prices $30.2 Million Public Offering of Common Stock
-
Lipocine Prices $30.2 Million Public Offering of Common Stock
-
Roth Capital Starts Mast Therapeutics (MSTX) at Buy
-
Speed Commerce Announces Closing of Registered Direct Offering
-
Speed Commerce Announces Closing of Registered Direct Offering
-
Roth Capital Maintains TG Therapeutics (TGTX) at 'Buy' Following IRAK4 Inhibitor Compounds Presentation
-
Roth Affirms Aduro Biotech (ADRO) at 'Buy'; Novartis' (NVS) Data Validates Mesothelin CAR-T
-
Biodel (BIOD) Closes 37.5M Common Stock Offering
-
Roth Capital Remains Positive on Peregrine Pharma (PPHM) Following Bavituximab Presentation
-
Roth Capital Starts SolarEdge Technologies (SEDG) at Buy
-
Pre-Open Stock Movers 4/20: (HQCL) (ADRO) (HAS) Higher; (AMPE) (FARO) (RCL) Lower (more...)
-
UPDATE: Roth Capital Starts ADURO BIOTECH (ADRO) at Buy, PT $74
-
Roth Capital Upgrades CECO Environmental (CECE) to Buy; Management, Growth Opportunities to Drive 2015
-
Roth Capital Starts Crossroads Systems (CRDS) at Buy

